CLYM Latest Press Releases

-- May 14, 2026 --

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress Globe Newswire 7:00 AM

-- May 12, 2026 --

Climb Bio to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 7, 2026 --

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- May 5, 2026 --

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts Globe Newswire 7:00 AM

-- April 28, 2026 --

Climb Bio, Inc. Announces $110.0 Million Private Placement Globe Newswire 7:00 AM

-- April 8, 2026 --

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 Globe Newswire 7:00 AM

-- April 7, 2026 --

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy Globe Newswire 7:00 AM

-- March 5, 2026 --

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- February 5, 2026 --

Climb Bio to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- January 8, 2026 --

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software